37 results about "Virus-neutralizing Antibody" patented technology

The invention discloses a human-derived anti-respiratory syncytial virus neutralizing antibody RS135 and application of the human-derived anti-respiratory syncytial virus neutralizing antibody RS135. The human neutralizing antibody specifically aiming at the F protein of the respiratory syncytial virus is successfully obtained by applying a phage antibody library technology; the obtained human neutralizing anti-respiratory syncytial virus F protein gene engineering antibody variable region gene, Fab antibody gene and full antibody gene under the characteristics of each antibody gene are utilized to obtain the human neutralizing anti-respiratory syncytial virus F protein gene engineering antibody. The antibody can be expressed and produced in prokaryotic cells, yeast cells, eukaryotic cells and any recombination system or any other reconstructed gene containing the antibody gene on the basis of the antibody, and an antibody product capable of neutralizing respiratory syncytial virus infection is obtained. And a specific antibody drug for clinically preventing and treating respiratory syncytial virus infection is prepared.

The invention provides a new bunyavirus neutralizing antibody screening method based on single cell BCR sequencing. The new bunyavirus neutralizing antibody screening method comprises the following steps: S1, collecting peripheral blood B cells of acute stage and recovery stage patients and healthy volunteers of new bunyavirus infected persons; s2, carrying out CD19 < + > CD38 < + > CD138 < + > magnetic bead separation to obtain a single-cell suspension; s3, constructing a single cell transcriptome and a BCR library, separating single cells by using a microfluidic system, and performing high-throughput sequencing; s4, analyzing a B cell subset, a BCR cloning amplification mode and a VJ gene pair enrichment characteristic through bioinformatics analysis; and S5, screening a specific BCR clone type related to the severity of the disease as a neutralizing antibody candidate target. The method provided by the invention provides powerful support for immune monitoring and vaccine design of new bunyavirus infection, and is expected to provide new strategies and methods for clinical treatment and prevention.

According to the RNA vaccine for porcine epidemic diarrhea and the preparation method of the RNA vaccine, the RNA vaccine is obtained through gene synthesis, in-vitro transcription and lipid nanoparticle wrapping, the current epidemic new PEDV strain can be rapidly dealt with, the research and development and production cycle of new vaccine development is shortened, and an effective technical means is provided for prevention and control of new variant virulent strains. The RNA vaccine for porcine epidemic diarrhea prepared by the invention is high in production efficiency, can generate a high-level porcine epidemic diarrhea virus neutralizing antibody and binding antibody in vivo, can effectively reduce the occurrence of piglet diarrhea, and has great popularization value for prevention and control of porcine epidemic diarrhea.

An anti-rabies virus neutralizing antibody and preparation and a use thereof. Provided is an anti-rabies virus neutralizing antibody, comprising a heavy chain variable region SEQ ID NO. 1-SEQ ID NO. 3, a light chain variable region SEQ ID NO. 4-SEQ ID NO. 5, and GAS. The anti-rabies virus neutralizing antibody has good neutralizing activity; a high isoelectric point provides advantages in the stability of antibody formulations; a high Tm value indicates good thermal stability; strong affinity with recombinant rabies virus glycoproteins shows promise for the mass production of rabies virus neutralizing antibodies, providing technical support for the preparation of low-cost, safe, and effective rabies passive immune formulations.

The invention relates to the technical field of biological detection, and particularly discloses an ELISA kit for detecting a neutralizing antibody of a severe fever with thrombocytopenia syndrome virus and an application method of the ELISA kit. The ELISA kit comprises an ELISA plate on which SFTSV receptor LRP1 protein is fixed, and an enzyme-labeled SFTSV Gn-8M, wherein the SFTSV receptor LRP1 protein is fixed on the ELISA plate; the SFTSV Gn-8M is an SFTSV membrane protein Gn mutant designed by the invention, and can be specifically combined with an SFTSV receptor LRP1 protein on an elisa plate, and compared with a standard virus strain Gn protein, the self-designed SFTSV Gn-8M has amino acid mutation of eight sites, has stronger combining capacity with a host cell receptor, and can be used for detecting the SFTSV. The kit disclosed by the invention has the characteristics of high safety, high efficiency, high flux, high specificity, high sensitivity, high stability and the like, and is suitable for large-scale rapid screening of the neutralizing antibody of the severe fever with thrombocytopenia syndrome virus.

The invention relates to a self-adjuvant based on a virus source glycopeptide and an application of the self-adjuvant in preparation of a vaccine, the self-adjuvant is a glycopeptide fragment based on a varicella-zoster virus (VZV) source, and the self-adjuvant is a B cell epitope structural domain V50 glycopeptide (from 50 valine to 135 isoleucine, V50-I135) in glycoprotein E. The invention further relates to a preparation method of the self-adjuvant based on the virus source glycopeptide and application of the self-adjuvant based on the virus source glycopeptide in preparation of the vaccine. The V50 glycopeptide and the novel coronavirus RBD are subjected to fusion expression and then are coupled to the surfaces of the nanoparticles based on ferritin to form the self-adjuvant vaccine, so that the levels of RBD specific antibodies and pseudovirus neutralizing antibodies induced by the RBD nanoparticle vaccine can be remarkably enhanced, and the V50 glycopeptide has a synergistic effect in B cell response and T cell response of systemic systemic immunity and mucosal immunity at the same time. The immune protection effect of the novel coronavirus RBD nanoparticle vaccine is obviously improved.

The application belongs to the technical field of bioinformatics analysis, and discloses a kind of anti-new coronavirus neutralizing antibody VJ gene preference analysis method, including antibody database acquisition data, data screening, selection frequency statistics, selection preference analysis, selection frequency and preference visualization, pairing frequency statistics, pairing preference analysis, pairing frequency and preference visualization.The beneficial aspects of the present application are that the neutralizing antibody and VJ selection and pairing frequency are tested by scientific statistical methods, and are visualized to make the result interpretation more simple and intuitive.Therefore, according to the above method, a new method for early prediction of anti-new coronavirus neutralizing antibody production based on peripheral blood B cell VJ gene frequency and preference is established, which can predict whether the probability of producing neutralizing antibody by the subject is higher than the baseline level of healthy people.

The application provides a preparation method of a shrimp iridovirus DIV1 neutralizing antibody and application thereof. The gene sequence shown as SEQ ID NO. 1 and the amino acid sequence shown as SEQ ID NO. 2 are used to solve the problem that there is no neutralizing antibody for the shrimp iridovirus DIV1 at present. The antibody for the shrimp iridovirus DIV1 prepared by the application can specifically recognize the DIVI virus and has good virus neutralizing activity, can effectively reduce the death of shrimps caused by DIV1 virus infection, significantly improve the ability of shrimps to resist DIV1 virus infection, and effectively prevent the infection and transmission of the virus.

Disclosed in the present application are an antibody against respiratory syncytial virus (RSV), a nucleic acid molecule encoding the antibody, an expression vector containing the nucleic acid molecule, a host cell containing the nucleic acid molecule or the vector, and a pharmaceutical composition containing the antibody. Further provided in the present application are a method for preparing and purifying the antibody and the use thereof.

The invention discloses a human expression optimized Nipah virus N gene and application thereof in preparation of Nipah pseudovirus, belongs to the technical field of biology, and constructs a segment of Nipah virus N gene sequence optimized by human cell expression codons and constructs a recombinant vector pcDNA3.1-NiV-N-opti. The recombinant vector pcDNA3.1-NiV-N-opti is used as a pseudovirus expression vector, the recombinant vector pcDNA3.1-NiV-N-opti and pseudovirus packaging plasmids are used for preparing the kit for the nipah pseudovirus, the nipah pseudovirus can be efficiently obtained, the titer of the obtained nipah pseudovirus is higher than that of the nipah pseudovirus packaged by an original sequence, and an unexpected technical effect is achieved. Besides, the Nipah pseudovirus has His, Myc and EGFP marks, the preparation effect of the pseudovirus can be visually observed, and the Nipah pseudovirus can be used for Nipah serological diagnosis, virus neutralizing antibody evaluation and the like and has a good application prospect.

This invention provides a fully human anti-H3N2 virus neutralizing antibody IAV-3 and its applications, belonging to the fields of microbiology and immunology. The amino acid sequence of the heavy chain variable region of the neutralizing antibody IAV-3 is shown in SEQ ID NO:1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:2; the amino acid sequence of the heavy chain constant region of the neutralizing antibody IAV-3 is shown in SEQ ID NO:3, and the amino acid sequence of the light chain constant region is shown in SEQ ID NO:4. The neutralizing antibody provided by this invention has the characteristics of high expression, fully human origin, and good stability, making it suitable for industrial production and possessing potential application value in responding to current and future influenza caused by the H3N2 virus.

The invention relates to the technical field of biology, in particular to a porcine rotavirus and porcine epidemic diarrhea virus bivalent subunit vaccine and application thereof, and the active ingredient of the vaccine is an antigen protein combination composed of VP4, VP7 and S1 protein. The three proteins have a synergistic enhancement effect during combined immunization, and the S1 protein can cooperate with VP4 and VP7 antigens to significantly improve the early humoral immune response level. Besides, the antigen combination can induce an organism to generate high-level specific antibodies and virus neutralizing antibodies and stimulate remarkable cellular immune response, and has good application potential in the aspect of combined prevention and control of the porcine rotavirus and the porcine epidemic diarrhea virus.

The present invention provides a group of compounds for the sequestration of Adeno-associated virus (AAV) and adenovirus (AdV) neutralizing antibodies (NAbs) in a patient. The compounds comprise an inert backbone conjugated with at least one recombinant peptide comprising an epitope. The epitope is a conserved epitope that is targeted by human anti-AAV or anti-AdV NAbs. The backbone where the conserved epitope is conjugated to is a poly-lysine (PLys) or poly-acrylamide (PAA) backbone, among others. Also provided is a pharmaceutical composition comprising this type of compounds, as well as a method for use to treat an individual to inhibit the immune reaction against an AAV or AdV-based therapy. It is also possible to use synthetic compounds for an in vitro detection of anti-AAV or anti-AdV NAbs in a sample.

This invention provides a dosage regimen for the treatment of BK or JC polyomavirus infection in human subjects. [Solution] The administration regimen includes the steps of (a) parenterally administering a dose of an antibody or antigen-binding fragment that specifically binds to the VP1 protein of the polyomavirus to the subject; (b) measuring the serum or tissue concentration of the antibody or antigen-binding fragment in the subject; and (c) measuring the serum or tissue trough concentration (C trough The administration regimen includes the step of administering a further dose of the antibody or its antigen-binding fragment before the concentration drops to less than approximately 3-860 μg / mL, wherein the concentration of the antibody or its antigen-binding fragment in the serum or tissue during the treatment is reduced to the C trough Maintain a higher position.

The invention discloses an anti-dengue virus neutralizing antibody E412C, a humanized antibody thereof, a multivalent antibody of the humanized antibody and application of the multivalent antibody. The antibody provided by the invention comprises three complementary determining regions CDR1, CDR2 and CDR3, the amino acid sequence of the CDR1 is the 26th to 33rd sites of SEQ ID NO: 1, the amino acid sequence of the CDR2 is the 51st to 58th sites of SEQ ID NO: 1, and the amino acid sequence of the CDR3 is the 97th to 114 sites of SEQ ID NO: 1. The antibody provided by the invention can be used for neutralizing four serotype dengue viruses (DENV I-IV). The antibody provided by the invention can be used for preventing and treating dengue virus infection, and has important biological and medical significance.

The present application relates to the technical field of biological medicine, in particular to a kind of mRNA vaccine for obtaining bovine nodular skin disease virus neutralizing antibody and application thereof.The mRNA vaccine, characterized in that, contain A27L antigen selected fragment, or L1R antigen selected fragment.The mRNA vaccine provided by the present application successfully induced effective immune response in mice and cattle, detected high level of serum neutralization titer, and the effect is better than goatpox live vaccine (CVCC AV41) vaccine, and the antibody induced has no antibody-dependent enhancement effect.This breakthrough fills the blank in the current LSDV vaccine research and development field, provides a new solution for the production and research and development of animal vaccine, and has very high commercial value and broad application prospect.

The invention discloses a hybridoma cell strain, a West Nile virus monoclonal antibody as well as a preparation method and application of the West Nile virus monoclonal antibody. The West Nile virus monoclonal antibody is secreted by a hybridoma cell strain WN-mAb-12, the hybridoma cell strain is preserved in the China Center for Type Culture Collection (the address is Wuhan University, Wuhan, China), the preservation number is CCTCC NO: C2024123, and the preservation date is April 23, 2024. The monoclonal antibody secreted by the hybridoma cell strain WN-mAb-12 can generate a neutralization effect on the West Nile virus, and has a good neutralization effect. By analyzing the biological characteristics of the West Nile virus, a technical support is laid for researching the protection mechanism of the West Nile virus neutralizing antibody and researching and developing clinical specific medicines in the future.

The present patent application relates to the fields of antibodies and polyomaviruses. More specifically, the present patent application relates to a human monoclonal antibody, or antigen- binding fragment thereof, directed against a polyomavirus, in particular BKV, and that is useful in the treatment of an infection by said polyomavirus or associated-disorder thereof.

The application discloses an anti-Western Nile virus neutralizing antibody WN-XH3 and application thereof. The antibody comprises a heavy chain variable region and a light chain variable region, has good binding activity with Western Nile virus E protein, and has strong virus neutralizing activity, thereby laying a foundation for diagnosis and treatment of Western Nile virus infection related diseases, development of a Western Nile virus infection related disease treatment drug and the like, and can be used as a candidate of a clinical anti-Western Nile virus drug, and has a good application prospect.

The invention discloses a human-derived anti-respiratory syncytial virus neutralizing antibody RS414 and application of the human-derived anti-respiratory syncytial virus neutralizing antibody RS414. The antibody RS414 is obtained by screening by using a phage surface presentation technology. The antibody specifically recognizes the respiratory syncytial virus particle antigen, aims at the F protein of the respiratory syncytial virus, has obvious enzyme-linked immunosorbent assay reaction with the respiratory syncytial virus, and has a neutralizing activity function of resisting respiratory syncytial virus infection. The antibody provided by the invention can be prepared into a specific antibody drug for preventing and treating respiratory syncytial virus infection, and can be used for clinically preventing or treating lower respiratory tract infection, especially severe lower respiratory tract infection (pneumonia and capillary bronchitis) caused by the respiratory syncytial virus.

The invention provides a novel adjuvant subunit rabies virus vaccine as well as a preparation method and application thereof, the vaccine takes a rabies virus (RABV) glycoprotein extracellular domain prepared by a gene recombination technology as an antigen, and takes a combination of CpG oligodeoxynucleotide and QS21 as an adjuvant. A contrast experiment is carried out on the vaccine, an LNP-mRNA-G-H270P vaccine, a commercial inactivated vaccine and an aluminum adjuvant subunit vaccine, and the result shows that the vaccine can induce a remarkably higher RABV-G specific IgG antibody and virus neutralizing antibody titer, and the humoral immune response is superior to that of other vaccines; meanwhile, moderate and effective Th1 type cell immune response can be induced, so that protective immunity can be supported; 100% protection is achieved in a lethal RABV attack experiment, and the protection effect is equivalent to that of an mRNA vaccine and is remarkably superior to that of an aluminum adjuvant vaccine and a commercial inactivated vaccine. The vaccine provided by the invention has a controllable immune activation mechanism and relatively high safety, avoids the storage risk and excessive inflammatory response of a nucleic acid technology, and is a more reliable and universal choice in the current vaccine technology.

Disclosed in the present application are an antibody against respiratory syncytial virus (RSV), a nucleic acid molecule encoding the antibody, an expression vector containing the nucleic acid molecule, a host cell containing the nucleic acid molecule or the vector, and a pharmaceutical composition containing the antibody. Further provided in the present application are a method for preparing and purifying the antibody and the use thereof.

The present patent application relates to the fields of antibodies and polyomaviruses. More specifically, the present patent application relates to a human monoclonal antibody, or antigen-binding fragment thereof, directed against a polyomavirus, in particular BKV, and that is useful in the treatment of an infection by said polyomavirus or associated-disorder thereof.

The application relates to a self-adjuvant based on a virus-derived glycopeptide and application thereof in preparation of a vaccine, the self-adjuvant being a varicella-zoster virus (VZV)-derived glycopeptide fragment, which is a B cell epitope domain V50 glycopeptide (from a valine at 50 to an isoleucine at 135, V50-I135) in a glycoprotein E. After fusion expression of the V50 glycopeptide and a novel coronavirus RBD, coupling on the surface of a ferritin-based nanoparticle, a self-adjuvant vaccine is formed, which can significantly enhance the RBD-specific antibody and pseudovirus neutralizing antibody levels induced by the RBD nanoparticle vaccine, and also has a synergistic effect in B cell response and T cell response of systemic and mucosal immunity. The immunoprotective effect of the novel coronavirus RBD nanoparticle vaccine is significantly improved.

The application provides a foot-and-mouth disease virus broad-spectrum neutralizing antibody, a neutralizing antibody competition ELISA detection kit and application, and belongs to the technical field of antibodies. The foot-and-mouth disease virus broad-spectrum neutralizing antibody has an amino acid sequence of a heavy chain variable region as shown in SEQ ID NO:1 and an amino acid sequence of a light chain variable region as shown in SEQ ID NO:2. The application further provides a foot-and-mouth disease virus neutralizing antibody competition ELISA detection kit, which comprises the following components: a detection plate with a foot-and-mouth disease virus 146S antigen, a biotin-labeled foot-and-mouth disease virus broad-spectrum neutralizing antibody and an enzyme-labeled avidin. The detection sensitivity of the kit is 100%, the specificity is more than 99.5%, the negative / positive coincidence rate compared with the gold standard method VNT for detecting neutralizing antibodies is 92.8%, and the kit can more accurately reflect the level of neutralizing antibodies in serum.

The present patent application relates to the fields of antibodies and polyomaviruses. More specifically, the present patent application relates to a human monoclonal antibody, or antigen-binding fragment thereof, directed against a polyomavirus, in particular BKV, and that is useful in the treatment of an infection by said polyomavirus or associated-disorder thereof.

The invention discloses an anti-dengue virus neutralizing antibody 2E22C as well as a humanized antibody, a multivalent specific antibody and application thereof. The antibody provided by the invention comprises three complementary determining regions CDR1, CDR2 and CDR3, the amino acid sequence of the CDR1 is the 26th to 33rd sites of SEQ ID NO: 1, the amino acid sequence of the CDR2 is the 51st to 58th sites of SEQ ID NO: 1, and the amino acid sequence of the CDR3 is the 97th to 117th sites of SEQ ID NO: 1. The antibody provided by the invention can neutralize four kinds of serotype dengue viruses (DENV I-IV). The antibody provided by the invention can be used for preventing and treating dengue virus infection, and has important biological and medical significance.